Compliance, adherence, persistence – causes and consequences of non-adherence to medical recommendations Review article

Main Article Content

Karolina Skóra

Abstract

Patients’ non-adherence is among the most serious health problems of mankind. It was recognized as one of the major barriers to achieving benefits from therapies based on current medical knowledge. The aim of this paper is to present basic information about the terminology describing the extent to which the patient follows therapeutic instructions and to outline the scale of the phenomenon and the essence of non-adherence. This paper also describes the causes and consequences of non-adherence. Adherence to therapy with proven clinical efficacy is the primary determinant in achieving the benefits of treatment. Unfortunately the problem of non-adherence is not a priority within scientific interests in Poland. This is reflected in fact that 35% of patients in Poland do not adhere to the recommended therapy. Non-adherence to long-term therapy for chronic illnesses in developed countries averages 50%. Non-compliance to medical recommendations is a multidisciplinary problem. No one has yet discovered a simple panacea that would eliminate this problem. Nowadays it seems to be important to raise awareness regarding the adherence crisis and refine the methods of improving adherence.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Article Details

How to Cite
1.
Skóra K. Compliance, adherence, persistence – causes and consequences of non-adherence to medical recommendations. OncoReview [Internet]. 2012Mar.30 [cited 2024Apr.18];2(1(5):54-0. Available from: https://journalsmededu.pl/index.php/OncoReview/article/view/294
Section
Articles

References

1. Sabate E.: Adherence to long-term therapies: evidence for action. World Health Organization 2003.
2. Miller N.H., Hill M., Kottke T., Ockene I.S.: The multilevel compliance challenge: recommendations for a call to action. A statement for healthcare professionals. Circulation 1997; 95: 1085-1090.
3. Simpson S.H., Eurich D.T., Majumdar S.R., Padwal R.S., Tsuyuki R.T., Varney J. et al.: A meta-analysis of the association between adherence to drug therapy and mortality. BMJ 2006 Jul 1; 333(7557): 15.
4. Fundacja Na Rzecz Wspierania Rozwoju Polskiej Farmacji i Medycyny: Polskiego pacjenta portret własny – raport o przestrzeganiu zaleceń terapeutycznych przez polskich pacjentów. Warszawa 2010.
5. Friemann K., Wciórka J.: Compliance – przeżytek czy termin użyteczny. Postępy Psychiatrii i Neurologii 2008; 17(4): 365-375.
6. National Collaborating Centre for Primary Care. National Institute for Health and Clinical Excellence. Online.
7. Cramer J.A., Roy A., Burrell A., Fairchild C.J., Fuldeore M.J., Ollendorf D.A. et al.: Medication Compliance and Persistence: Terminology and Definitions. Value Health 2008 Jan-Feb; 11(1): 44-7.
8. opis odsyłacza Projekt ABC – Ascertaining Barriers for Compliance. [online: www.abcproject.eu].
9. Osterberg L., Blaschke T.: Adherence to Medication. N. Engl. J. Med. 2005; 353: 487-497.
10. Współpraca lekarza z pacjentem w chorobach przewlekłych – compliance, adherence, persistence. Stan obecny i możliwości poprawy. Gaciong Z., Kuna P.Z. (red.). Medycyna po Dyplomie 2008 Marzec; Supl. 03/08.
11. Pechere J.C., Hughes D., Kardas P., Cornaglia G.: Non-compliance with antibiotic therapy for acute community infections: A global survey. International Journal of Antimicrobial Agents 2007 Mar; 29(3): 245-53.
12. DiMatteo M.R.: Variations in Patients’ Adherence to Medical Recommendations: A Quantitative Review of 50 Years of Research. Medical Care 2004 Mar; 42(3): 200-9.
13. Holloway K., van Dijk L.: Rational Use of Medicines. The World Medicines Situation 2011 3rd Edition. Geneva: World Health Organization, 2011.
14. Dezii C.M.: Medication noncompliance: what is the problem? Manag. Care 2000 Sep; 9(9 Suppl): 7-12.
15. DiMatteo M.R.: Future directions in research on consumer – provider communication and adherence to cancer prevention and treatment. Patient Education and Counseling 2003 May; 50(1): 23-6.
16. Cramer J.A.: Medicine partnerships. Heart 2003 May; 89(Suppl. 2): ii19-ii21.
17. Jones J.K., Gorkin L., Lian J.F., Staffa J.A., Fletcher A.P.: Discontinuation of and changes in treatment after start of new courses of antihypertensive drugs: a study of a United Kingdom population. BMJ 1995 Jul 29; 311(7000): 293-5.
18. Claxton A.J., Cramer J., Pierce C.: A Systematic Review of the Associations Between Dose Regimens and Medication Compliance. Clin. Ther. 2001 Aug; 23(8): 1296-310.
19. Simpson R.J.: Challenges for Improving Medication Adherence. JAMA 2006 Dec 6; 296(21): 2614-6.
20. Thompson A.M., Dewar J., Fahey T., McCowan C.: 2007 Breast Cancer Symposium. In Association of poor adherence to prescribed tamoxifen with risk of death from breast cancer; 2007. San Francisco, Abstract No: 130.
21. MEGAVOICE IRELAND LTD.: A Low Cost, Environmentally, Friendly Smart Packaging Technology to Differentiate European SME Suppliers to Service the Needs of the Blind, Illiterate and Europe’s Aging Population. Online .
22. Ernst F.R., Grizzle A.J.: Drug-Related Morbidity and Mortality: Updating the Cost-of-Illness Model. J. Am. Pharm. Assoc. (Wash.) 2001 Mar-Apr; 41(2): 192-9.
23. DATAMONITOR: Addressing Patient Compliance: Targeted Marketing Driving a Shift in Focus From Acquisition to Retention (2004). Online.
24. Improving Patient Treatment Adherence: A Clinician’s Guide. Bosworth H. (red.). Springer, 2010.
25. Haynes R.B., Ackloo E., Sahota N., McDonald H.P., Yao X.: Interventions for enhancing medication adherence (Review). The Cochrane Library. 2008.